Evidence map›Paper›PMID 18991293›Full record

ArticleEuropean journal of immunology2008

The role of the PI3K-AKT kinase pathway in T-cell development beyond the beta checkpoint.

Ling Xue, Leslie Chiang, Chulho Kang, Astar Winoto

Open access · bronzeAbstract read
In one paragraph

Article in European journal of immunology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. The Multifaceted Role of CMA in Glioma: Enemy or Ally?International journal of molecular sciences · 2021
    Review
  11. Diverse Roles of Akt in T cells.Immunometabolism · 2021
    Article
  12. Review
  13. Article
  14. Article
  15. Therapeutic Options for Aggressive T-Cell Lymphomas.Current hematologic malignancy reports · 2017
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Ling XueCancer Research Laboratory, University of California, Berkeley, CA 94720, USA.
Leslie Chiang
Chulho Kang
Astar Winoto
University of California, Berkeley · US

Funding

PROGRAMMED CELL DEATH IN NORMAL AND MALIGNANT T CELLSR01CA066236 · NCI · UNIVERSITY OF CALIFORNIA BERKELEY · PI WINOTO, ASTAR · 1995 to 2014
$4.7M
NCI NIH HHS R01 CA066236
6 · The paper itself

Abstract

The PI3K-AKT pathway can mediate diverse biological responses and is crucial for optimal immune responses and lymphocyte development. Deletion of PI3K subunits or AKT leads to blockage of T-cell development at the TCR-beta checkpoint. Studies with over-expression of constitutively activated AKT have implicated this pathway in anti-apoptosis of developing thymocytes and in development of regulatory T cells. However, the role of endogenous PI3K-AKT in T-cell development beyond the TCR-beta checkpoint remains unclear. Here, we inhibited the endogenous PI3K-AKT pathway in thymocytes after double negative stages by expressing the negative regulator, PTEN. These mice exhibit normal early T-cell development, but the transition from intermediate single positive to double positive (DP) thymocytes is inhibited, leading to a significantly decreased number of DP, single positive thymocytes and peripheral T cells. Proliferation of peripheral T cells is reduced but apoptosis of DP cells and subsequent T-cell maturation, including regulatory T cells, are normal. AKT phosphorylation can be readily observed in most WT T-cell compartments but not DP thymocytes in response to TCR activation. Thus, the PI3K-AKT pathway is crucial for the transition of intermediate single positive to DP thymocytes but is dispensable for apoptosis and maturation of developing thymocytes.

Indexed as

AnimalsApoptosisMiceMice, TransgenicPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktPTEN PhosphohydrolaseReceptors, Antigen, T-CellSignal TransductionT-LymphocytesPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktPTEN PhosphohydrolasePten protein, mouseReceptors, Antigen, T-Cell

Identifiers

PMID18991293
PMCPMC2614442
OpenAlexW2030078792

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.